Periowave™ Photodisinfection System is a simple, pain-free, non-surgical and non-antibiotic approach for the treatment of gum disease (periodontitis, endodontics, peri-implant disease).
Toronto, Ontario (PRWEB) August 08, 2011
Periowave Dental Technologies, Inc., is developing and commercializing antimicrobial photodynamic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections in the oral cavity without encouraging the formation and spread of antibiotic resistance. The photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London.
The company’s Periowave™ Photodisinfection System is a simple, pain-free, non-surgical and non-antibiotic approach for the treatment of gum disease (periodontitis, endodontics, peri-implant disease) and other oral infections. Photodisinfection is a powerful non-thermal antimicrobial technology that has been proven in clinical trials to generate superior patient outcomes such as gains in clinical attachment and reductions in pocket depth and bleeding without requiring any patient compliance. This new license agreement will allow the company to expand the indications for its Photodisinfection technology.
Periowave Dental Technologies, Inc., is based in Toronto, Ontario, Canada. For additional information and to learn more about Periowave and photodisinfection technology, please contact info(at)periowave(dot)com or visit the Company's website at: http://www.periowave.com